

USSN 09/577,468
Amendment dated 14 November 2003
Reply to Office action of 26 September 2003

REMARKS

In response to the Examiner's comments, claim 10 is canceled without prejudice to pursuit of the subject matter in a related application. Accordingly, claims 1-4, 8-9, and 11 are currently pending.

I. Formal matters.

Claim 10 was objected to under 37 CFR 1.75(c) and for containing a misspelling. The objections are rendered moot by cancellation of claim 10.


II. Provisional Rejection Under Obviousness-Type Double Patenting.

Claims 1-4 and 8-11 were provisionally rejected under the judicially created doctrine of obvious-type double patenting over claims 1-3, and 8-9 of co-pending Application No. 09/454,380. Applicants have previously agreed to file a terminal disclaimer upon indication of allowable claims. A terminal disclaimer is accordingly herein attached. This rejection may now be withdrawn.

Conclusion

In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged. The Office action of 26 Sept 2003 set a 3 month period for reply to 26 Dec 2003. This Amendment document is submitted within the response period with a statutory Terminal Disclaimer. Accordingly, the fee due is \$110 under 37 CFR § 1.20(d). If any further fees should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

18-0650
Respectfully submitted


Valeta Gregg, Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400